Showing results (11-20 of 150) with videos related to
Sort By:
Pageof 15
F1000Prime Reports|May 27, 2014
Geriatric considerations in the treatment of advanced prostate cancerElizabeth R Kessler, Thomas W FlaigOncology (Williston Park, N.Y.)|March 8, 2012
Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approachesE David Crawford, Thomas W FlaigExpert Opinion on Pharmacotherapy|October 22, 2008
Management of the side effects of androgen deprivation therapy in men with prostate cancerThomas W Flaig, L Michael GlodéDrugs & Aging|November 9, 2012
Optimal management of recurrent prostate cancer in older patientsElizabeth R Kessler, Thomas W FlaigBladder Cancer (Amsterdam, Netherlands)|August 15, 2020
Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder CancerPeter Boxley, Melissa Plets, Thomas W FlaigNature Reviews. Clinical Oncology|November 28, 2012
Clinical opportunities and challenges in targeting tumour dormancyJonathan A Hensel, Thomas W Flaig, Dan TheodorescuClinical Genitourinary Cancer|October 18, 2020
Prostate Cancer Central Nervous System Metastasis in a Contemporary CohortPeter J Boxley, Derek E Smith, Dexiang Gao, et al.Pharmacotherapy|July 29, 2008
Bicalutamide-associated fulminant hepatotoxicityCindy L O'Bryant, Thomas W Flaig, Kenneth J UtzOncology (Williston Park, N.Y.)|May 22, 2013
Targeted therapy in advanced urothelial carcinomaBrandon P Verdoorn, Elizabeth R Kessler, Thomas W FlaigOncology Reports|September 3, 2010
VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cellsYuan Li, Xiaoping Yang, Lih-Jen Su, et al.Pageof 15